Report Library
View More
HR+/HER2- Breast Cancer KOL Intervi...
September 22, 2023
Datamonitor Healthcare CV&Met: Veno...
September 22, 2023
Datamonitor Healthcare Oncology: Sm...
September 22, 2023
HER2+ Breast Cancer KOL Interview -...
September 21, 2023
Datamonitor Healthcare Oncology Dis...
September 21, 2023
Datamonitor Healthcare Oncology: Gl...
September 21, 2023
Datamonitor Healthcare CV&Met: Amyl...
September 21, 2023
Datamonitor Healthcare CNS: Insomni...
September 21, 2023
HER2+ Breast Cancer KOL Interview -...
September 20, 2023
Datamonitor Healthcare CNS Disease ...
September 20, 2023
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 9/21/23 | Intarcia | ITCA 650 for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/19/23 | Intarcia | ITCA 650 for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/13/23 | Alnylam (ALNY) | Onpattro for Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/12/23 | Humacyte (HUMA) | Humacyl for Peripheral Arterial Disease (PAD) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/12/23 | AbbVie (ABBV) | Skyrizi for Crohn's Disease | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 09/23/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 09/23/23 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (U.S.) |
| 09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
